CUPERTINO, Calif., Jan. 24 /PRNewswire/ — DURECT Corporation
(Nasdaq: DRRX) today announced that Evelyn R. Robledo has been promoted to
Vice President of Quality Assurance and Compliance.
Ms. Robledo joined DURECT in March 2000 and, utilizing her solid
understanding of FDA regulations, developed and implemented an effective
Quality Assurance System to support DURECT’s product development and
commercial activities. The breadth of her background in both pharmaceuticals
and medical devices has proven to be a valuable asset to DURECT as the company
moves its pharmaceutical systems development programs through the product
development phases, and continues to sustain its ongoing commercial business.
Ms. Robledo’s background includes a Bachelor of Science degree from
Catholic University in Puerto Rico, and 25 years of experience in the quality
area of FDA regulated businesses. Her proven track record includes her role
as a Director of Quality Assurance and Quality Control at Molecular
Biosystems, followed by a position as Vice President of Quality Assurance and
Quality Control of Cygnus Inc., and most recently as a Principal of Quality
Systems at Sensible Solution Engineering, a private consulting firm.
Ms. Robledo played a key role in achieving DURECT’s milestone of moving
the first product development program, DUROS sufentanil, for the treatment of
chronic pain, into a Phase II clinical trial in December 2000. James E.
Brown, Chief Executive Officer of DURECT, remarked, “As DURECT continues to
expand, we look forward to continuing to draw on Ms. Robledo’s experience and
vision to grow our quality organization to meet the requirements of regulatory
bodies as well as DURECT’s business needs.”
DURECT Corporation is pioneering the development and commercialization of
pharmaceutical systems to deliver the right drug to the right site in the
right amount at the right time. DURECT’s pharmaceutical systems combine
technology innovations from the medical device and drug delivery industries
with proprietary pharmaceutical and biotechnology drug formulations. These
capabilities can enable new drug therapies or optimize existing therapies
based on a broad range of compounds, including small molecule pharmaceuticals
as well as biotechnology molecules such as proteins, peptides and genes.
DURECT’s initial portfolio of products combine the DUROS technology, a proven
and patented drug delivery platform licensed for specified fields of use from
ALZA Corporation, with drugs for which medical data on efficacy and safety are
available. Founded in 1998, the Company is headquartered in Cupertino, CA.
The Company’s World Wide Web site can be accessed at http://www.www.durect.com.
To join DURECT’s email alert service, please register by selecting “Email
Alerts” on the main Investor Relations web page at http://www.www.durect.com.
DUROS is a registered trademark of ALZA Corporation.
For further information please contact: DURECT Corporation Noonan/Russo Communications Schond L. Greenway Tom Baker Director, Investor Relations Media Relations Phone: (408) 777-1417 Phone: (415) 677-4455 Ext. 370 Schond.Greenway@Durect.com T.Baker@NoonanRusso.com
SOURCE DURECT Corporation
CONTACT: Schond L. Greenway Director, Investor Relations of DURECT
Corporation, 408-777-1417, Schond.Greenway@Durect.com; or Tom Baker, Media
Relations of Noonan-Russo Communications, 415-677-4455, Ext. 370,
T.Baker@NoonanRusso.com, for DURECT Corporation/